On December 9, China-fof announced its 2024 annual rankings, with CEC Capital once again taking the top position on the "2024 Best FA Institutions" list. This marks the second consecutive year that CEC Capital has ranked first, following its leadership on the 2023 list.

In 2024, CEC Capital successfully completed several significant transactions, including:

?     BlueSail Medical’s asset spin-off and financing

?     CiVi Biopharma’s nearly $100 million licensing transaction

?     ROKID’s RMB 500 million financing

?     Moon Biotech’s RMB 300 million financing 

?     Microcyto’s RMB 300 million financing

Throughout 2024, CEC Capital has received multiple prestigious industry honors, including:

?     "2024 China’s Most Influential Boutique Investment Bank" by 36Kr

?     "China’s Most Influential Boutique M&A Investment Bank" by 36Kr

?     "China’s Boutique Investment Bank in the Healthcare Sector" by 36Kr

?     "2023 China’s Best Emerging Investment Bank Top 5" by China Venture LIST

?     "2023 Healthcare Financial Advisor of the Year" by Vbdata

These accolades further cement CEC Capital’s position as a leading financial advisor in the industry.